Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Influence of Polymorphisms and Cholesterol-Lowering Treatment on SCARB1 mRNA Expression

Full text
Cerda, Alvaro [1] ; Genvigir, Fabiana Dalla Vecchia [1] ; Rodrigues, Alice Cristina [1] ; Vieira Willrich, Maria Alice [1] ; Dorea, Egidio Lima [2] ; Silveira Bernik, Marcia Martins [2] ; Arazi, Simone Sorkin [1] ; de Oliveira, Raquel [1] ; Hirata, Mario Hiroyuki [1] ; Crespo Hirata, Rosario Dominguez [1]
Total Authors: 10
[1] Univ Sao Paulo, Dept Clin & Toxicol Anal, Fac Pharmaceut Sci, BR-05508900 Sao Paulo - Brazil
[2] Univ Sao Paulo, Univ Hosp, BR-05508900 Sao Paulo - Brazil
Total Affiliations: 2
Document type: Journal article
Source: JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS; v. 18, n. 8, p. 640-651, 2011.
Web of Science Citations: 9

Aim: This study evaluated the influence of polymorphisms and cholesterol-lowering treatments on SCARB1 mRNA expression in peripheral blood mononuclear cells and in HepG2 and Caco-2 cells. Methods: Blood samples were drawn from normolipidemic (NL, n = 166) and hypercholesterolemic (HC, n = 123) individuals to extract DNA and total RNA and to analyze the lipid profile. After a 4-week washout period, 98 HC individuals were treated with atorvastatin (10 mg/day/4 weeks) whereas 25 were treated with ezetimibe (10 mg/day/4 weeks), followed by simvastatin (10 mg/day/8 weeks) and simvastatin plus ezetimibe (10 mg each/day/4 weeks). HepG2 and Caco-2 cells were treated with atorvastatin, simvastatin and ezetimibe at various concentrations for 12 and 24 h and collected for RNA extraction. SCARB1 mRNA expression was measured by TaqMan (R) assay and SCARB1 c.4G > A, c.726 + 54C > T and c.1080C > T polymorphisms were detected by PCR-RFLP. Results: High LDL cholesterol (> 160 mg/dL) values were associated with low baseline SCARB1 mRNA expression in PBMC. Allele T carriers for SCARB1 c.726 + 54C > T had lower basal SCARB1 transcription in PBMC (p < 0.05). Simvastatin, atorvastatin and ezetimibe treatments did not modify the SCARB1 mRNA level in PBMC from HC patients. Similarly, these cholesterol-lowering drugs did not modulate the SCARB1 expression in HepG2 and Caco-2 cells in spite of the concentration and time of exposure (p > 0.05). Conclusion: LDL cholesterol levels and SCARB1 c.726 + 54C > T are associated with low mRNA expression in mononuclear cells. Cholesterol-lowering drugs do not modulate SCARB1 expression in PBMC from HC subjects or in HepG2 and Caco-2 cells. (AU)

FAPESP's process: 09/15125-8 - Influence of cholesterol synthesis and absorption on expression of proteins of the cholesterol reverse transport in HepG2 and CACO-2 cells
Grantee:Rosario Dominguez Crespo Hirata
Support type: Regular Research Grants